Digital Therapeutics Have Arrived But Will Insurers Get On Board?
Executive Summary
Will FDA-cleared prescription digital therapeutics be able to follow wellness, chronic disease and sleep disorder apps onto the formularies of major payers? For digital therapeutics companies investing in randomized controlled clinical trials, GMP manufacturing and FDA submissions for products, the current absence of public health insurance coverage is frustrating.
You may also be interested in...
Translating Psychedelic Experiences Into Targeted Health Outcomes: Optimism And Concern
A panel of executives, academics and experts discussed the potential for psychedelic therapies, such as MDMA and psilocybin, to revolutionize behavioral health in a recent Demy Colton virtual salon. But with nearly 50 publicly traded companies now developing psychedelics, some panelists expressed concern about a rush to market, and “competition and domination” harshening the buzz.
BI Finds Right Fit For Digital Therapeutic Partnership With Click
Deal Snapshot: The firms are partnering on a digital therapeutic for schizophrenia in a deal potentially worth $500m.
Post-COVID-19 Consumer Preferences Provide Roadmap For Strategy Across Health Care Sectors
Post-COVID, a consumer’s home as point of care has led to greater acceptance for health gadgets while shifting preferences away from injectables, shows a new study, which has pointers for pharma strategy. With anxiety over the pandemic continuing, mental telehealth solutions are ripe for the picking.